{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-24-000028","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.243289+00:00","generated_at":"2026-06-01T04:27:15.124086+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Mineralys Therapeutics appoints Dr. Alexander Gold to board; Dr. Olivier Litzka resigns","bullets":["Appointed Alexander M. Gold, M.D. as Class I director and to Nominating and Corporate Governance Committee, effective June 13, 2024.","Dr. Gold received options to purchase 44,000 shares vesting over three years; cash compensation per non-employee director program.","Dr. Olivier Litzka resigned from board effective June 13, 2024, with no disagreement with company or management.","Board size decreased from eight to seven following resignation and prior departure of Alexander Asam, Ph.D. on May 22, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-24-000028","json":"https://secwatch.observer/filing/0001933414-24-000028.json","markdown":"https://secwatch.observer/filing/0001933414-24-000028.md","text":"https://secwatch.observer/filing/0001933414-24-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/0001933414-24-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/mlys-20240613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:27:15.124086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"128d1601a1","claim":"Olivier Litzka resigned as Director at Mineralys Therapeutics, Inc..","evidence_excerpt":"Olivier Litzka, Ph.D. informed the Board of his decision to resign from the Board, effective June 13, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/0001933414-24-000028-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1fe78e9f45","claim":"Alexander M. Gold was appointed as Class I director at Mineralys Therapeutics, Inc..","evidence_excerpt":"the Board appointed Alexander M. Gold, M.D. as a member of the Board and the Nominating and Corporate Governance Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000028/0001933414-24-000028-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}